Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02460900 · ClinicalTrials.gov registry record · Phase 3
Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke
A Phase 3 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 3
- Development phase
- 184
- Enrollment target
NCT02460900 is a Phase 3 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 184 participants.
The verdict
NCT02460900, a Phase 3 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 184 participants
- Enrollment target
Study Summary
The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV/AIDS who smoke. Results of this study will provide crucial, real world evidence of the best way for healthcare providers to help smokers living with HIV/AIDS quit smoking.
Interventions
- DRUG Placebo
- DRUG Varenicline
- BEHAVIORAL Standard of Care
- BEHAVIORAL Positively Smoke Free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2016-07 |
| Est. Completion | 2021-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02460900
The ClinicalTrials.gov registry entry for NCT02460900 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 184 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02460900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02460900 about?
NCT02460900 is a clinical study titled "Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke". The single greatest health behavior change that could improve cardiovascular morbidity and associated mortality is to assist people living with HIV/AIDS who smoke to quit. The investigators will use a factorial design to evaluate the most promising behavioral and pharmacologic treatments aimed at ac...
What is the current status of trial NCT02460900?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 184 participants. The study started on 2016-07. Estimated completion is 2021-04.
What interventions are being tested in trial NCT02460900?
The interventions under investigation include: Placebo (DRUG), Varenicline (DRUG), Standard of Care (BEHAVIORAL), Positively Smoke Free (BEHAVIORAL).
Who is sponsoring clinical trial NCT02460900?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.